Clinical analysis of childhood and adolescent Hodgkin's lymphoma: a report of 88 cases.
- Author:
Pu-yuan XING
1
;
Yuan-kai SHI
;
Xiao-hui HE
;
Li-qiang ZHOU
;
Mei DONG
;
Jian-liang YANG
;
Peng LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bleomycin; therapeutic use; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; therapeutic use; Dacarbazine; therapeutic use; Disease-Free Survival; Doxorubicin; therapeutic use; Female; Follow-Up Studies; Hodgkin Disease; complications; drug therapy; pathology; radiotherapy; Humans; L-Lactate Dehydrogenase; blood; Male; Mechlorethamine; therapeutic use; Neoplasm Staging; Prednisone; therapeutic use; Procarbazine; therapeutic use; Retrospective Studies; Splenomegaly; etiology; Survival Rate; Vinblastine; therapeutic use; Vincristine; therapeutic use
- From: Chinese Journal of Oncology 2012;34(9):692-697
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe aim of this study was to investigate the clinicopathological characteristics, effective treatment and prognosis in childhood and adolescent Hodgkin's lymphoma.
METHODSA total of 88 patients with childhood and adolescent Hodgkin's lymphoma were treated in the Cancer Hospital of CAMS from 1998 to 2005. The clinicopathological and follow-up data of the patients were retrospectively reviewed. The survival rate was calculated by Kaplan-Meier method and compared by log-rank test. COX multivariate prognosis analysis was performed.
RESULTSThe 2-year event-free survival rate of the 88 patients was 86.4%, the 5-year event-free survival rate was 61.4%, and the 5-year overall survival rate was 95.5%. Univariate analysis showed that the stage of disease (P = 0.033), "B" symptoms (P = 0.028), bulky disease (P = 0.007), splenomegaly (P = 0.050), LDH elevation (P = 0.020), chemotherapy regimen (P = 0.003) were prognostic factors in the 5-year event-free survival rate. Splenomegaly (P = 0.039), LDH elevation (P = 0.033), chemotherapy regimen (P = 0.008) were prognostic factors of 5-year overall survival rate. Multivariate analysis showed that chemotherapy regimen (P = 0.033), stage of disease (P = 0.023), LDH elevation (P = 0.008), "B" symptoms (P = 0.044), bulky disease (P = 0.009) were independent prognostic factors of 5-year event-free survival rate. The chemotherapy regimen (P = 0.012) and LDH elevation (P = 0.046) were independent prognostic factors of 5-year overall survival rate.
CONCLUSIONSThe non-ABVD chemotherapy regimen, stage IV disease, LDH elevation, associated with "B" symptoms and bulky disease are independent prognostic factors of 5-year event-free survival rate. LDH elevation and non-ABVD chemotherapy regimen are independent prognostic factors of 5-year overall survival rate.
